Default

Cell Technology, Inc.

No Reviews Yet
No Completed Orders
Fremont, California, US

About Cell Technology, Inc.

Cell Technology was founded in 1998 to provide research solutions for the academic, biotechnology and pharmaceutical industries. Our focus is to develop unique assays that allow researchers to study cellular functions using cell permeable reagents. This process allows in situ detection of cell or tissue specific events while maintaining morphology and architecture.

Our Services (3)


ic

ADCC and CDC Assays

Price on request

Cell Technology possesses a customizable ADCC/CDC/CMC assay platform that facilitates the selection of antibody drug candidates. Our bioluminescent ultra sensitive aCella-TOX Assay, is rapidly becoming the standard for ADCC/CDC/CMC assays within the therapeutics industry. Please click here for a direct comparison between the aCella-TOX and (51Cr) Chromium Release Methods

We provide ADCC/CDC assay services to determine the activity of the antibody and/or complement against specified target cell lines . The result would be, a dose dependent kinetic response of the therapeutic antibody. The assay service includes optimization of E/T ratios, measurement of ADCC / CDC activity at a series of antibody concentrations, at a certain E:T ratio. Correlation data with FACS analysis can be generated upon request.


ic

Polymorphism Screening

Price on request

We developed a flow cytometry-based test for this polymorphism using a mAb that recognized only the FcγRIIIA-158 V allele (antibody 1) in combination with a mAb that detected both FcγRIIIA-158 alleles (antibody 2). The ratio between the mean fluorescence intensity (MFI) measured with those mAbs (Table 1) in a single individual predicted the FCGR3A genotype with 100% sensitivity and specificity.


ic

Flow Cytometry

Price on request

We developed a flow cytometry-based test for this polymorphism using a mAb that recognized only the FcγRIIIA-158 V allele (antibody 1) in combination with a mAb that detected both FcγRIIIA-158 alleles (antibody 2). The ratio between the mean fluorescence intensity (MFI) measured with those mAbs (Table 1) in a single individual predicted the FCGR3A genotype with 100% sensitivity and specificity.


Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.
KP

Krunal Patel

VP of Opearations and Finance

Cell Technology, Inc. has not received any reviews.

Cell Technology, Inc. has not received any endorsements.